High Cell Surface Death Receptor Expression Determines Type I Versus Type II Signaling
| Autor: | Gregory J. Gores, Steve F. Bronk, Haiming Dai, Paula A. Schneider, Scott H. Kaufmann, Daniel D. Billadeau, Xue Wei Meng, Jin San Zhang, Alexander Koenig, Sun Hee Lee, Kevin L. Peterson |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Janus kinase 1
Fas-Associated Death Domain Protein Receptor expression Cell Biology Biology Fas receptor Biochemistry Fas ligand Cell biology TNF-Related Apoptosis-Inducing Ligand Jurkat Cells Mice Gene Expression Regulation Hes3 signaling axis Death-inducing signaling complex biology.protein Animals Humans fas Receptor FADD Signal transduction Molecular Biology Signal Transduction |
| Zdroj: | Journal of Biological Chemistry. 286:35823-35833 |
| ISSN: | 0021-9258 |
| DOI: | 10.1074/jbc.m111.240432 |
| Popis: | Previous studies have suggested that there are two signaling pathways leading from ligation of the Fas receptor to induction of apoptosis. Type I signaling involves Fas ligand-induced recruitment of large amounts of FADD (FAS-associated death domain protein) and procaspase 8, leading to direct activation of caspase 3, whereas type II signaling involves Bid-mediated mitochondrial perturbation to amplify a more modest death receptor-initiated signal. The biochemical basis for this dichotomy has previously been unclear. Here we show that type I cells have a longer half-life for Fas message and express higher amounts of cell surface Fas, explaining the increased recruitment of FADD and subsequent signaling. Moreover, we demonstrate that cells with type II Fas signaling (Jurkat or HCT-15) can signal through a type I pathway upon forced receptor overexpression and that shRNA-mediated Fas down-regulation converts cells with type I signaling (A498) to type II signaling. Importantly, the same cells can exhibit type I signaling for Fas and type II signaling for TRAIL (TNF-α-related apoptosis-inducing ligand), indicating that the choice of signaling pathway is related to the specific receptor, not some other cellular feature. Additional experiments revealed that up-regulation of cell surface death receptor 5 levels by treatment with 7-ethyl-10-hydroxy-camptothecin converted TRAIL signaling in HCT116 cells from type II to type I. Collectively, these results suggest that the type I/type II dichotomy reflects differences in cell surface death receptor expression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|